Understanding Public Attitudes Toward Cannabis Legalization: Qualitative Findings From a Statewide Survey

Resko, Stella M.; Ellis, Jennifer D.; Early, Theresa J.; Szechy, Kathryn A.; Rodriguez, Brooke; Agius, Elizabeth

doi:10.1080/10826084.2018.1543327

Cited by 49 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…34 Additionally, researchers reported that individuals in favour of MC supported it's legalization as they felt it would become easier to study and allow for a thorough investigation into the therapeutic bene ts of MC. 32 This complements the ndings within our paper which suggest that MC policies require support from a greater degree of empirical evidence and clinical research in order to facilitate MC regulation.…”

Section: Signi Cance Of Findings and Comparative Literaturesupporting

confidence: 77%

“…2 In addition, evidence demonstrates that countries that allow MC have higher rates of public support for its legalization in comparison to countries that do not allow MC, identifying a possible reciprocal relationship. 32 A recurring barrier we identi ed was the need for more clinical and political evidence to inform future MC policies. This urgency can be echoed throughout the literature, as the National Academies of Sciences, Engineering, and Medicine outlined the lack of evidence required for US policymakers to make sound decisions regarding the use of cannabis in their 2017 national report.…”

Section: Signi Cance Of Findings and Comparative Literaturementioning

confidence: 99%

See 1 more Smart Citation

Facilitators and Barriers to the Regulation of Medical Cannabis: A Scoping Review of the Peer-Reviewed Literature

Ruheel

Gomes

Usman

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: In recent decades, several political, legislative, and judicial processes around the world have advanced legalization efforts for the use of medical cannabis (MC). As MC usage evolves through legislative reform, with an increase in public acceptance and therapeutic potential, a need exists to further investigate the facilitators and barriers to MC regulation.Methods: A scoping review was conducted to identify the facilitators and barriers associated with the implementation of international MC regulations. MEDLINE, EMBASE, AMED and PsycINFO databases were systematically searched. Eligible articles included primary studies that evaluated the MC regulatory framework of one or more countries globally.Results: Twenty-two articles were deemed eligible and included in this review. Themes identified include: (1) effects of conflicts, mindset and ideology of state population, (2) the use of comparisons to analyze MC regulation, and (3) the need for more knowledge, advice and empirical/clinical evidence to inform future MC policies.Conclusion: We identified a number of facilitators and barriers to MC regulation and provide a holistic overview of what factors are proposed to affect MC regulation. In recognizing that the evidence-base surrounding MC, MC usage among patients, and general societal acceptance of MC are all increasing across many parts of the globe, our review allows for relevant stakeholders to better understand these facilitators and barriers to inform future MC policy making.

show abstract

Section: Signi Cance Of Findings and Comparative Literaturesupporting

confidence: 77%

Section: Signi Cance Of Findings and Comparative Literaturementioning

confidence: 99%

Facilitators and Barriers to the Regulation of Medical Cannabis: A Scoping Review of the Peer-Reviewed Literature

Ruheel

Gomes

Usman

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In the US, recreational cannabis legalization may have contributed to increases in positive attitudes toward cannabis use and, ultimately, increases in consumption. 4,6,37,38 Several policy mechanisms exist, including restricting the maximum potency, increasing tax and the introduction of minimum unit pricing, which may increase the safety of cannabis use while minimizing increases in prevalence. 39 These policies should be combined with adequate public communication regarding the risks of cannabis use.…”

Section: Discussionmentioning

confidence: 99%

Trends and correlates of cannabis use in Canada: a repeated cross-sectional analysis of national surveys from 2004 to 2017

Lowry

Corsi

2020

cmajo

View full text Add to dashboard Cite

I n October 2018, the Government of Canada legalized the recreational use of cannabis nationally. 1 Before legalization, cannabis was the most widely used illicit drug in Canada, 2 and consumption increased from 14% to 17% between 2018 and 2019. 3 This rise may be a result of the increases in cannabis availability and circulation, and decreases in the perception of harm. 4,5 Surveys suggest that in the United States, the social acceptability of cannabis has increased 6 and perceptions of harm have decreased after recreational use was legalized in several states. 7 Trends in cannabis consumption may vary by sex, age, ethnicity and socioeconomic status and may be influenced by changing social norms and new legislation. 8,9 Studies that assess the differences in cannabis use trends across relevant socioeconomic and demographic groups are essential to inform legislation and public health priorities around cannabis consumption in Canada and among vulnerable populations. In this study, we combined 3 national survey platforms in Canada to evaluate and compare trends in cannabis use between 2004 and 2017 by age, sex, level of education, recent pregnancy and province. Methods We followed the recommendations of Burns and Kho 10 and the STROBE statement 11 to report the methodology used in this repeated cross-sectional study. Setting The surveys included in this study were conducted in Canadian provinces between 2004 and 2017. The surveys covered all people in Canada aged 15 years or older residing in the 10 provinces. Exclusions included residents of the Yukon, Northwest Territories and Nunavut and populations living in

show abstract

“…The public seems to assume the safety of cannabis and its constituents from a long history of recreational use in mostly younger persons or personal use earlier in life [17,18]. Cannabis is generally viewed as a safer alternative to prescription drugs due to its natural origin and because it has become ubiquitous throughout the U.S. via medical and recreational legalization [19]. Safety is further assumed given that consumer CBD-based products are widely available over the counter for recreational and complementary health uses.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry

Brown

Costales

Boemmel-Wegmann

et al. 2020

JCM

View full text Add to dashboard Cite

Use of medical marijuana is increasing in the United States and older adults are the fastest growing user group. There is little information about the characteristics and outcomes related to medical marijuana use. This study is a descriptive analysis of older adults (aged ≥50 years old) who were early adopters of a medical marijuana program in the U.S. state of Florida. Per state legislation, initial and follow-up treatment plans were submitted to the University of Florida College of Pharmacy. Data collection included demographics, clinical history, medical conditions, substance use history, prescription history, and health status. Follow-up treatment plans noted changes in the chief complaint and actions taken since the initial visit. Of the state’s 7548 registered users between August 2016 and July 2017, N = 4447 (58.9%) were older adults. Patients utilized cannabidiol (CBD)-only preparations (45%), preparations that had both tetrahydrocannabinol (THC) and CBD (33.3%) or were recorded to use both CBD-only and THC + CBD products (21.7%). The chief complaints indicating medical cannabis treatment were musculoskeletal disorders and spasms (48.4%) and chronic pain (45.4%). Among other prescription medications, patients utilized antidepressants (23.8%), anxiolytics and benzodiazepines (23.5%), opioids (28.6%), and cardiovascular agents (27.9%). Among all drug classes with potential sedating effects, 44.8% of the cohort were exposed to at least one. Patients with follow-up visits (27.5%) exhibited marked improvement as assessed by the authorizing physicians. However, the patient registry lacked detailed records and linkable information to other data resources to achieve complete follow up in order to assess safety or efficacy. Future improvements to registries are needed to more adequately capture patient information to fill knowledge gaps related to the safety and effectiveness of medical marijuana, particularly in the older adult population.

show abstract

Understanding Public Attitudes Toward Cannabis Legalization: Qualitative Findings From a Statewide Survey

Cited by 49 publications

References 23 publications

Facilitators and Barriers to the Regulation of Medical Cannabis: A Scoping Review of the Peer-Reviewed Literature

Facilitators and Barriers to the Regulation of Medical Cannabis: A Scoping Review of the Peer-Reviewed Literature

Trends and correlates of cannabis use in Canada: a repeated cross-sectional analysis of national surveys from 2004 to 2017

Characteristics of Older Adults Who Were Early Adopters of Medical Cannabis in the Florida Medical Marijuana Use Registry

Contact Info

Product

Resources

About